Anthony Davies considers the possibility of a new CMC norm in this BPI article

February 14, 2020

Categories

CEO Anthony Davies sitting at head of conference table, gesturing expansively and smiling

In this Feb 2020 bioprocessintl.com article (click here), Dan Stanton talks to Dark Horse CEO Anthony Davies about what pattern Catalent's $315M acquisition of Masthercell might be foreshadowing.

Sara Mills co-authors "Process evolution in C and GT from discovery to commercialization"

Anthony offers insights with Endpoints News

The long road to affordability: a cost of goods analysis for an autologous CAR-T process

Why is Demand & Supply Planning in the Life Sciences so Difficult?

Stay Informed

Subscribe to our mailing list for the latest insights on advanced therapy development, regulatory updates, industry trends, and upcoming events from Dark Horse Consulting Group.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

We respect your privacy. Unsubscribe at any time. We will never sell your information.